Double maintains 2 strategies that include SYRE - Spyre Therapeutics, Inc.
SeekingAlpha
Phase 1 data for Spyre Therapeutics, Inc.'s SPY002 & SPY072 show promise in autoimmune treatments. Advancing to Phase 2 trials. Click for my updated look at SYRE.
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced positive interim Phase 1 results from its first-in-human trials of SPY002 (formerly SPY002-091) and SPY072 (formerly SPY002-072), two investigational, novel, extended half-life monoclonal antibodies targeting
Finnhub
Presentation Operator MessageOperator Good morning, ladies and gentlemen, and welcome to the Spyre Therapeutics SPY002 Phase I interim data call. [Operator Instructions] This call is being recorded
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced it will report interim results from the Phase 1 SPY002 healthy volunteer trials on Tuesday, June 17, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00am ET to discus
Finnhub
Presenter SpeechKyuwon Choi Okay. Thank you for joining us. I'm Paul Choi, and I cover biotechnology here at the firm. It's our pleasure to welcome Spyre, and we have Cameron here on stage with...
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 50,200 shares of common stock of Spyre to three n
Current Value
$15.531 Year Return
Current Value
$15.531 Year Return
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 69.76% | $4.82B | 0.35% |
| IBB | 65.27% | $5.26B | 0.45% |
| GNOM | 64.41% | $44.57M | 0.5% |
| PBE | 60.91% | $223.19M | 0.58% |
| ARKG | 60.81% | $1.02B | 0.75% |
| IWC | 59.70% | $818.14M | 0.6% |
| IWO | 59.41% | $11.60B | 0.24% |
| BBH | 58.80% | $330.62M | 0.35% |
| PINK | 58.63% | $130.57M | 0.5% |
| IWM | 58.27% | $63.72B | 0.19% |
| VTWO | 58.23% | $12.52B | 0.07% |
| KJUL | 57.94% | $119.50M | 0.79% |
| SCHA | 57.87% | $17.26B | 0.04% |
| QQQJ | 57.38% | $621.52M | 0.15% |
| NUSC | 57.17% | $1.14B | 0.31% |
| XPH | 57.09% | $147.96M | 0.35% |
| ESML | 56.99% | $1.84B | 0.17% |
| ISCG | 56.95% | $681.20M | 0.06% |
| KOMP | 56.72% | $2.29B | 0.2% |
| FBT | 56.58% | $1.01B | 0.54% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BEAM | 57.60% | $2.00B | -15.33% | 0.00% |
| CGON | 56.41% | $2.03B | -13.46% | 0.00% |
| IDYA | 54.75% | $1.92B | -34.15% | 0.00% |
| SYNA | 54.56% | $2.63B | -22.41% | 0.00% |
| XNCR | 54.49% | $590.72M | -55.40% | 0.00% |
| APGE | 54.39% | $2.64B | +18.19% | 0.00% |
| DIOD | 53.89% | $2.63B | -21.82% | 0.00% |
| DNLI | 53.31% | $2.16B | -30.05% | 0.00% |
| CRNX | 52.70% | $2.76B | -33.39% | 0.00% |
| ACLX | 52.58% | $3.66B | +21.24% | 0.00% |
| VSH | 52.51% | $2.31B | -23.47% | 2.34% |
| LFUS | 52.43% | $5.87B | -6.00% | 1.17% |
| IPGP | 52.23% | $3.12B | -13.24% | 0.00% |
| IMNM | 52.03% | $750.92M | -28.80% | 0.00% |
| COGT | 51.82% | $843.67M | -11.36% | 0.00% |
| IQV | 51.78% | $28.48B | -20.39% | 0.00% |
| KRYS | 51.78% | $4.08B | -20.39% | 0.00% |
| LSCC | 51.76% | $7.19B | -16.13% | 0.00% |
| LGND | 51.69% | $2.19B | +37.44% | 0.00% |
| KLIC | 51.03% | $1.94B | -25.30% | 2.20% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ZCMD | -0.01% | $29.55M | -8.59% | 0.00% |
| NOC | -0.02% | $71.81B | +14.14% | 1.69% |
| CCEC | -0.21% | $1.02B | +3.91% | 2.58% |
| LMT | 0.23% | $108.37B | -0.75% | 2.81% |
| K | -0.32% | $27.76B | +41.17% | 2.85% |
| TR | 0.49% | $2.57B | +22.68% | 1.02% |
| MNOV | 0.71% | $62.29M | -9.29% | 0.00% |
| BTI | 0.73% | $103.67B | +50.78% | 6.33% |
| MVO | 0.85% | $66.47M | -37.17% | 21.45% |
| AQB | -0.89% | $2.96M | -53.35% | 0.00% |
| UUU | -0.90% | $7.17M | +101.30% | 0.00% |
| CALM | 0.93% | $5.50B | +65.97% | 6.64% |
| CCI | 0.95% | $44.93B | +6.73% | 5.62% |
| CNK | 0.98% | $3.47B | +41.29% | 0.53% |
| CORT | -1.03% | $7.57B | +133.90% | 0.00% |
| TEF | -1.10% | $30.08B | +25.41% | 6.16% |
| CTRE | -1.46% | $5.88B | +20.77% | 4.04% |
| GFI | 1.54% | $21.56B | +57.55% | 2.31% |
| HRL | 1.62% | $16.94B | +1.88% | 3.74% |
| PPC | -1.68% | $10.84B | +33.46% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -43.64% | $99.63M | 0.59% |
| VIXY | -43.13% | $164.54M | 0.85% |
| BTAL | -41.39% | $296.22M | 1.43% |
| IVOL | -24.12% | $347.03M | 1.02% |
| FTSD | -17.16% | $231.81M | 0.25% |
| SPTS | -16.19% | $5.80B | 0.03% |
| FXY | -15.57% | $816.38M | 0.4% |
| XONE | -14.46% | $625.28M | 0.03% |
| VGSH | -13.64% | $22.80B | 0.03% |
| SCHO | -12.44% | $11.03B | 0.03% |
| IBTH | -11.69% | $1.62B | 0.07% |
| UTWO | -10.75% | $379.52M | 0.15% |
| IBTI | -10.73% | $1.06B | 0.07% |
| TBLL | -10.49% | $2.13B | 0.08% |
| IBTG | -10.39% | $1.92B | 0.07% |
| ULST | -10.16% | $654.75M | 0.2% |
| STPZ | -9.79% | $450.47M | 0.2% |
| LDUR | -9.22% | $929.65M | 0.5% |
| IBTJ | -8.78% | $688.19M | 0.07% |
| TPMN | -8.77% | $30.70M | 0.65% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -17.49% | $24.23B | +35.36% | 1.09% |
| ED | -13.08% | $36.00B | +12.64% | 3.34% |
| CME | -12.78% | $99.39B | +40.68% | 3.86% |
| HUSA | -9.19% | $19.66M | -19.53% | 0.00% |
| BTCT | -8.82% | $25.56M | +61.14% | 0.00% |
| MO | -8.43% | $99.67B | +28.77% | 6.90% |
| VZ | -7.58% | $183.79B | +6.01% | 6.18% |
| STG | -7.31% | $30.78M | -22.51% | 0.00% |
| EXC | -7.26% | $43.33B | +23.58% | 3.62% |
| AEP | -6.52% | $55.16B | +17.93% | 3.54% |
| VHC | -6.25% | $48.19M | +108.24% | 0.00% |
| AWK | -6.03% | $27.36B | +9.65% | 2.21% |
| NEUE | -5.52% | $61.24M | +29.92% | 0.00% |
| AMT | -5.46% | $104.32B | +14.40% | 3.00% |
| CL | -5.28% | $74.88B | -3.64% | 2.19% |
| COR | -4.71% | $56.44B | +30.86% | 0.74% |
| KMB | -4.68% | $43.92B | -3.75% | 3.75% |
| T | -3.79% | $203.71B | +51.55% | 3.92% |
| LITB | -3.42% | $21.24M | -78.57% | 0.00% |
| SO | -3.21% | $100.18B | +17.28% | 3.18% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| UDN | -0.03% | $148.33M | 0.78% |
| BUXX | -0.03% | $315.18M | 0.25% |
| TBIL | 0.12% | $5.81B | 0.15% |
| DFNM | -0.18% | $1.57B | 0.17% |
| GVI | -0.21% | $3.42B | 0.2% |
| GOVT | -0.27% | $27.54B | 0.05% |
| OWNS | -0.30% | $129.31M | 0.3% |
| NYF | -0.32% | $892.18M | 0.25% |
| USDU | -0.36% | $162.43M | 0.5% |
| KCCA | 0.38% | $109.43M | 0.87% |
| STXT | -0.47% | $129.40M | 0.49% |
| NEAR | -0.49% | $3.34B | 0.25% |
| AGZD | 0.50% | $102.70M | 0.23% |
| FMHI | 0.62% | $754.85M | 0.7% |
| AGGH | 0.67% | $324.95M | 0.29% |
| FXE | 0.77% | $568.94M | 0.4% |
| UUP | -0.87% | $201.63M | 0.77% |
| BAB | 0.94% | $933.45M | 0.28% |
| JMST | 1.07% | $4.06B | 0.18% |
| TIPX | 1.12% | $1.74B | 0.15% |
